Your business development partner and strategic advisor
BioPharma Capital, LLC provides life sciences focused strategic and financial advisory services, including M&A advisory, strategic partnering and transaction process management.
We are dedicated to maximizing value for our clients using credible scientific and evidence driven approaches. Our clients are typically pharmaceutical and biotech companies considering partnering, out-licensing, divestitures, fund raising or corporate sales.
Our team provides decades of experience in transaction support, healthcare strategy consulting, pricing and market access, forecasting, investment banking and translational research. We understand the science and technology behind the assets we represent and we have vast expertise managing transactions.
Strategy and negotiation for transformative life science transactions
We run disciplined sell-side processes for biotech and pharma assets. We identify the right buyers and partners, position your program against their priorities, and manage outreach so it creates real competitive tension.
Our positioning rests on rigorous analysis: a composite valuation built from multiple secondary sources and backed by more than 1,000 primary research interviews with clinicians, payers, and experts across the US and EU. That depth lets us defend value and structure terms that capture it.
Numbers alone don’t close deals. Process does. We keep timelines moving, handle multiple bidders, and negotiate firmly at the table. We stay with you from first outreach through signing, so the final terms reflect the full value of your asset or company.
We are dedicated to creating value for life science companies
We specialize exclusively in life sciences strategic advisory and transaction services. Our clients have included 15 of the top 20 pharma/biotech companies and dozens of small and mid-size biotech and spec pharma companies. We have experience working across all stages of the product lifecycle, from research collaborations and lead identification to in-line growth strategies and lifecycle planning.
Partner with us to provide strategic direction and drive towards optimal transactions
Our Approach
BioPharma Capital (BPC) offers strategic and financial advisory services focused on creating value for emerging life science companies
Who We Are
- Our team is passionate about maximizing value for our clients using credible scientific and evidence-driven strategies
- We have decades of experience in transaction advisory, health care strategy consulting, pricing and market access, forecasting, investment banking, and translational research
Creation
Who We Serve
- Our clients are typically emerging pharmaceutical and biotech companies considering partnering, licensing, co-development, co-promotion, or corporate sales
- We work with assets in all therapy areas and in all stages of development, from pre-clinical discovery to marketed products
- 2 Senior Advisors, 3 Project Managers, 4 Analysts
- Access to highly qualified teams as-needed via professional networks
- Licensing, Partnering, Co-Promotion, and M&A
- Due diligence, structuring, negotiations and valuation analyses
- Serve as outsourced or extension of internal BD team
- Our flexible fee structures align incentives and accommodate client needs
Discussions with potential partners require strategic negotiations skills, persistence, and analytical rigor
BPC offers the focus, expertise and experience to successfully navigate partnering negotiations
Negotiations
- Lead and participate in non-confidential and confidential discussions
- Maintain active communication with your company team and coordinate scheduling with external parties including bidders and other vendors
- Provide guidance on term sheet valuations and counteroffers
Financial Modeling & Deal Structuring
- Build and maintain a model to generate term sheets and create rationale for offers/counteroffers or alternate structures that accommodate different viewpoints between partners
- Adapt NPV model as new insights on inputs are gained and use new outputs to adapt deal materials accordingly
Data room
- Monitor data room activities as per degree of visibility defined by host site
- Update materials to adapt to possible partner concerns
We offer services tailored specifically to biopharma deal-making that are designed to surpass both IB and consulting offerings
| Transaction Advisor | Rigorous, Data-Driven Life-Science Market Insights | Will go at-risk with clients to align interests | Extensive Networks | Deal brokering and execution |
|---|---|---|---|---|
| Investment Banks | ||||
| Healthcare Consultants | ||||
| BioPharma Capital |
BioPharma Capital has capabilities and resources to provide strategic transaction advisory to life science companies
Strategic Advisory
An emphasis on optimizing value
BioPharma Capital, LLC has in-depth knowledge and global resources for emerging biopharma companies.
M&A
M&A Sell-Side Engagements
We can help you
- Refine your pitch using our deep expertise in the pharmaceutical industry and understanding of what resonates with potential acquirers
- Credibly articulate and validate your commercial opportunity by leveraging available third-party healthcare data and analytics
- Target acquirers through our vast network in the life sciences industry
Partnering/Licensing Engagements
We can help you
- 01
Refine your pitch using our deep expertise in the pharmaceutical industry and understanding of what resonates with potential partners
- 02
Credibly articulate your commercial opportunity by accessing third-party healthcare data and analytics
- 03
Target both global and regional partners through our vast network in the life sciences industry
- 04
Structure transactions including upfront payments, milestones and royalties
- 05
Negotiate and execute transactions
BPC ensures that the engagement process is well-orchestrated and runs at the proper cadence
Our process is designed to provide the most opportunities to solicit interest from the broadest possible set of potential partners and achieve the most favorable terms
BPC quantifies term sheets to facilitate comparison of offers and provide guidance on counter-offers
- Quantification of deal terms enables a uniform comparison of offers with differing milestones and payment options
- Our analysis forms the basis for developing counter-offers to potential partners, and a supporting rationale to use in negotiations
Case Studies
Case studies available on request
Contact Us
Financing
With BioPharma Capital you have a valued partner
We seek to understand and target the right investors that align with our clients’ objectives and management style.
A Partner to Our Clients
We raise capital for our clients to accelerate growth by
- 01
Accessing our vast network of healthcare investors
- 02
Helping to successfully articulate their value and potential to investors
- 03
Developing independent, third-party valuation analyses leveraging the multitude of data and expertise available to BioPharma Capital to credibly support pre-money valuations
- 04
Leveraging our experience to structure the financing and negotiate terms
A Resource to Strategic Partners
BioPharma Capital provides sophisticated pharma and biotech companies with unique pre-screened deal flow, offering an efficient way to identify opportunities that suit your business development objectives.
We conduct rigorous due diligence on potential opportunities, specifically screening for
Compelling science
Robust intellectual property
Experienced management team
Attractive commercial potential
Sound business strategy
Clear roadmap to value creation
Representative Transactions
Representative transactions available on request
Contact Us
Transactions
The BPC Team has supported over $13B in announced transaction value
$1B siRNA 2MW7141 Global License
Sell-side Advisor
$2.6B Disitamab Vedotin Global License
Sell-side Advisor
$400M Acquisition of
Buy-side Advisor
$1.26B Acquisition of
Co-Sell-side Advisor
$850M Co-Dev/Co-Promo
Buy-side Advisor
Undisclosed Collaboration and Option to Acquire
Sell-side Advisor
$310M Acquisition of
Sell-side Advisor
$230M Acquisition of
Buy-side Advisor
$650M Acquisition of
Buy-side Advisor
Undisclosed Option for Oncology Program
Sell-side Advisor
$290M KB001 Global License
Sell-side Advisor
Gabapentin SR US License
Sell-side Advisor
Not Exhaustive
2021 RemeGen–Seagen deal was highly covered by top media outlets in the industry
Seagen and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin
08/09/2021
– Seagen Licenses Disitamab Vedotin, a Novel HER2-targeted Antibody-Drug Conjugate (ADC) from RemeGen –
– Disitamab Vedotin has Shown Potential as a Differentiated ADC Across a Range of HER2 Expressing Tumors and is Being Developed as Monotherapy and in Combination with PD-1 Inhibitors, Further Expanding and Complementing Seagen’s Deep and Diverse Pipeline –
– Agreement Leverages Seagen and RemeGen’s Leadership and Expertise in Developing ADCs as well as Seagen’s Global Development and Commercialization Capabilities –
BOTHELL, Wash. & YANTAI, China--(BUSINESS WIRE)-- Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and RemeGen Co., Ltd. (9995.HK), a leading innovative biopharmaceutical company in China, today announced that the two companies have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted ADC.
Disitamab vedotin combines the drug-linker technology originally developed by Seagen with RemeGen’s novel HER2 antibody exhibiting higher affinity and an increased internalization rate as compared to trastuzumab in preclinical models.1, 2 As monotherapy, disitamab vedotin has demonstrated antitumor activity in
In $2.6B cancer deal, Seagen bets China's first homemade ADC can challenge Roche, AZ-Daiichi
Seagen Strikes $2.6 Billion ADC Deal with China’s RemeGen
Seagen, formerly known as Seattle Genetics, forged an exclusive licensing agreement with China’s RemeGen Co., Ltd, to develop and commercialize disitamab vedotin, a novel HER2-targeted antibody drug conjugate (ADC). The deal is valued at about $2.6 billion.
Disitamab vedotin combines the drug-linker technology developed by Seagen with RemeGen’s novel HER2 antibody.
RemeGen-Seagen was ranked as the largest out-licensing deal from China in 2021
Top 10 China Out-Licensing deals in 2021
| Licensee | Licensor | Regional Right | Assets | Disease Area | Deal Value (US$m) | |
|---|---|---|---|---|---|---|
| Seagen | RemeGen | Global | Disitamab Vedotin | Oncology | 2600 | |
| Novartis | BeiGene | ex-China | tislelizumab | Oncology | 2200 | |
| Lilly | Regor Therapeutics | ex-China | GLP-1R | Metabolic Disease | 1500 | |
| FibroGen | HiFiBio | Global | Galectin-9, and exclusive option for CXCR6 and CCR8 | Oncology | 1125 | |
| Coherus | Junshi Biosciences | US and Canada | Toripalimab | Oncology | 1110 | |
| Novartis | BeiGene | ex-China | Ociperlimab (BGB-A1217) | anti-cancer therapy | 1000 | |
| Biogen | InnoCare | ex-China | orelabrutinib | Autoimmune | 937.5 | |
| ArriVent | Allist | ex-China | furmonertinib | Oncology | 805 | |
| BeiGene | Nanjing Leads Biolabs | ex- China | LBL-007 Anti-LAG-3 Antibody | Oncology | 742 | |
| Flame Biosciences | NovaRock Biotherapeutics (Subsidiary of CSPC) | ex- Greater China | NBL-015 | Oncology | 640 |
Source: “2021 China Biopharma Review”, MSQ Analytics, January 11th, 2022
BioPharma Capital Team Members
Our team is comprised of individuals with business development, licensing, investment banking, and pricing and market access expertise. We understand the science and technology behind the assets we represent and we have vast expertise managing transactions. This combination of talent and a network of connections provides our clients with exceptional service.
Current responsibility
- Pitch, negotiate and close successful transactions on behalf of clients
- Continue to expand professional network amongst strategic buyers and institutional investors
Profile overview
- Experienced in several therapeutic areas
- Expanded BD advisory relationship with RemeGen, serving as Chief Business Officer 2022-2024
- Previously served as Chairman, President and CEO of IMS Health Capital
- Started in health care at SalomonSmithBarney Investment Banking Division (New York / London)
Education
- M.B.A. from Stanford University Graduate School of Business
- Bachelor’s degree from San Diego State University
Areas of expertise
- Deal brokering
- Strategic advisory
- Transaction structuring
- Negotiations
- Valuation
Relevant experience
- M&A, Financing, Partnering Transactions
- Business development strategy consulting
Any testimonial or endorsement may not be representative of the experience of other customers and is no guarantee of future performance or success.
Contact Info
BioPharma Capital, LLC
- Office
- La Jolla, CA
USA
Dan Ross, MBA
- Role
- Managing Partner
- Phone
- +1 619 208-8439
- dan@biopharmacapital.com
Privacy Policy
BioPharma Capital takes great care to safeguard the privacy of the personal information that we collect about our customers. This notice is provided to you so that you will understand what personal information we collect and how we use it.
We may collect non-public personal information from you from the following sources:
- Information that you provide to us during our process and to update your records. This may include your name, address, Social Security number, employment and financial information.
- Information we collect from third parties. This may include such things as information about transactions between you and third parties (trading history and account balances) and data that we may obtain from non-affiliated third parties, including consumer and industry reporting agencies.
- Information that we create and retain based on your investment experience with us. This may include records of previous transactions and the results of those transactions. BioPharma Capital uses the non-public information we collect to help us determine the suitability of our recommendations, as a tool in obtaining your investment objectives and to satisfy the requirements of various regulatory entities.
BioPharma Capital has adopted policies and procedures designed to safeguard your non-public personal information about existing or former customers to non-affiliated third parties. Only properly authorized employees are permitted access to non-public personal information. Our company records are kept in locations we consider to be secure. We use technology that is designed to protect the privacy of the information transmitted and received.
It is our policy not to disclose nonpublic personal information about existing or former customers to non-affiliated third parties, except as permitted by law. However, we do disclose and will continue to disclose such non-public personal information to non-affiliated third parties in response to a subpoena for records, to assist regulators and law enforcement agencies to prevent actual or potential fraud, money laundering, acts of terrorism or other illegal activity, to comply with an inquiry by a government agency or other regulator or as necessary for other legal purposes.
BioPharma Capital strives to keep your records accurate and to make appropriate corrections when you notify us. Please let us know if there is incorrect information in any statements or other communications that you receive from us.
We may modify our privacy policies in the future. If we do so, we will communicate any material changes to you as required by law. You should be aware that other parties with whom you have a relationship may have different privacy policies.
Terms of Use
Legal disclosures
Securities offered through Ashland Securities, LLC, a registered broker/dealer (member FINRA and SIPC).
For non-clients of the firm, BioPharma Capital, LLC’s website is limited to the dissemination of general information pertaining to the services it provides. Please contact the Firm at (619) 208-8439 to find out if we may conduct securities business in the state or country where you reside. Neither BioPharma Capital nor Ashland Securities, LLC effects or attempts to effect transactions in securities through this website. Any subsequent, direct communication with a prospective client regarding securities shall be conducted by an Ashland Securities, LLC registered representative who is either registered or qualifies for an exemption or exclusion from registration in the state or country where the prospective client resides.
Notice of risk
Nothing on this site should be interpreted to state or imply that past results are an indication of future performance. This site does not constitute a complete description of our services and is for informational purposes only. It is in no way a solicitation or an offer to sell securities or services. Information throughout this internet site, whether company information, charts, articles, or any other statements regarding market or other financial information, is obtained from sources which we believe reliable, but we do not warrant or guarantee the timeliness or accuracy of this information. We shall be liable for any errors or inaccuracies, regardless of cause, or the lack of timeliness of, or for any delay or interruption in the transmission thereof to the user. All investments involve risk, including foreign currency exchange rates, political risks, different methods of accounting and financial reporting, and foreign taxes.
Tax or legal considerations
BioPharma Capital, LLC is not in the business of providing tax or legal advice and each investor should consult qualified counsel. This site is not intended to render tax or legal advice.
Terms
BioPharma Capital, LLC operates this Web site to provide online access to information about BioPharma Capital, LLC and the services and opportunities we provide. Your access and use of this Web site is subject to the following terms and conditions and constitutes acceptance of these terms (“Terms of Use”). BioPharma Capital, LLC reserves the right to modify these Terms of Use at any time without giving you prior notice. Your use of the Web site following any such modification constitutes your agreement to follow and be bound by the Terms of Use as modified.
Disclaimer
The content available on this site is provided for informational and educational purposes only. It is not intended as an offer or solicitation for the purchase or sale of a financial instrument or securities and should not be viewed as, or relied upon as, an investment recommendation or advice. No representations or warranties are made as to the accuracy, completeness, or timeliness of this site’s content. The content available on this site is not intended to provide legal, tax, or accounting advice. Use of any of the content herein, including information, materials and opinions given and discussed, is at the User’s risk. Users are encouraged to discuss the information with any legal, tax, accounting or other professional deemed necessary to understand the risks and uncertainties implicit in investing.
License and access
You may use the Web site, and the information, writings, images and/or other works that you see, hear or otherwise experience on the Web site (singly or collectively, the “Content”) solely for your non-commercial, personal purposes and/or to learn about BioPharma Capital, Inc services. No right, title or interest in any Content is transferred to you, whether as a result of downloading such Content or otherwise. BioPharma Capital, Inc reserves complete title and full intellectual property rights in all Content. Except as expressly authorized by these Terms of Use, you may not use, alter, copy, distribute, transmit, or derive another work from any Content obtained from the Web site, except as expressly permitted by these Terms of Use.
Copyright
You may not, without BioPharma Capital, Inc’s permission, “mirror” any Content contained on the Web site or any other server. Except as specified above, nothing contained herein shall be construed as conferring by implication, estoppel or otherwise any license or right under any trademark, patent, copyright, or any other intellectual property right of BioPharma Capital, Inc or any third party.
Trademarks
The trademarks, logos, service marks, brand identities, title, characters, trade names, graphics, designs, and other properties (collectively the “Trademarks”) displayed on the BioPharma Capital Web site are protected intellectual properties that are registered and unregistered trademarks of BioPharma Capital and others. Nothing contained on the BioPharma Capital Web site should be construed as granting, by implication, or otherwise, any license or right to use any Trademark displayed on this Web site without the written permission of BioPharma Capital or such third party that may own the Trademark displayed on BioPharma Capital’s Web site. Your misuse of the Trademarks displayed on BioPharma Capital’s Web site, or any other content on BioPharma Capital’s Web site, except as provided herein, is strictly prohibited.
Privacy
See BioPharma Capital’s Privacy Policy.
Information provided to BioPharma Capital
BioPharma Capital does not want you to, and you should not, send any confidential or proprietary information to BioPharma Capital via the Web site. Any submission by you to BioPharma Capital, including but not limited to questions, comments, suggestions or the like shall be deemed to be non-confidential and shall become the property of BioPharma Capital. Furthermore, by your submission you grant BioPharma Capital an unrestricted, irrevocable license to use, reproduce, display, perform, modify, transmit, and distribute such information. BioPharma Capital shall be free to use any ideas, concepts, know-how or techniques contained in such information for any purpose whatsoever, including but not limited to developing, manufacturing, and marketing products incorporating such information.
Disclaimer of warranties
BIOPHARMA CAPITAL MAKES NO EXPRESS OR IMPLIED WARRANTIES, REPRESENTATIONS OR ENDORSEMENTS WHATSOEVER WITH RESPECT TO THE WEB SITE OR THE CONTENT. BIOPHARMA CAPITAL EXPRESSLY DISCLAIMS ALL WARRANTIES OF ANY KIND, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE AND NON-INFRINGEMENT, WITH REGARD TO THE WEB SITE, THE CONTENT, AND ANY SERVICE FURNISHED OR TO BE FURNISHED VIA THE WEB SITE.
BIOPHARMA CAPITAL DOES NOT WARRANT THE ACCURACY OR COMPLETENESS OF THE CONTENT, OR THAT ANY ERRORS IN THE CONTENT WILL BE CORRECTED. THE WEB SITE AND THE CONTENT ARE PROVIDED ON AN “AS IS” AND “AS AVAILABLE” BASIS.
Limitation of liability
IN NO EVENT WILL BIOPHARMA CAPITAL BE LIABLE FOR ANY DAMAGES WHATSOEVER, INCLUDING, BUT NOT LIMITED TO ANY DIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY OR OTHER INDIRECT DAMAGES ARISING OUT OF (I) THE USE OF OR INABILITY TO USE THE WEB SITE OR THE CONTENT, (II) ANY TRANSACTION CONDUCTED THROUGH OR FACILITATED BY THE WEB SITE; (III) ANY CLAIM ATTRIBUTABLE TO ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE WEB SITE, THE SERVICE AND/OR THE CONTENT, (IV) UNAUTHORIZED ACCESS TO OR ALTERATION OF YOUR TRANSMISSIONS OR DATA, OR (V) ANY OTHER MATTER RELATING TO THE WEB SITE, OR THE CONTENT, EVEN IF BIOPHARMA CAPITAL HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. IF YOU ARE DISSATISFIED WITH THE WEB SITE, THE CONTENT, OR WITH THE TERMS OF USE, YOUR SOLE AND EXCLUSIVE REMEDY IS TO DISCONTINUE USING THE WEB SITE.
BECAUSE SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF LIABILITY FOR CONSEQUENTIAL OR INCIDENTAL DAMAGES, SOME OF THE ABOVE LIMITATIONS MAY NOT APPLY TO YOU. IN SUCH STATES, BIOPHARMA CAPITAL’S LIABILITY IS LIMITED AND WARRANTIES ARE EXCLUDED TO THE GREATEST EXTENT PERMITTED BY LAW, BUT SHALL, IN NO EVENT, EXCEED $100.00.